Benzodiazepine use in medical cannabis authorization adult patients from 2013 to 2021: Alberta, Canada

Cerina Dubois,Heidi Fernandes,Mu Lin,Karen J. B. Martins,Jason R. B. Dyck,Scott W. Klarenbach,Lawrence Richer,Ed Jess,John G. Hanlon,Elaine Hyshka,Dean T. Eurich
DOI: https://doi.org/10.1186/s12889-024-18356-6
IF: 4.5
2024-03-22
BMC Public Health
Abstract:Benzodiazepines are a class of medications that are being frequently prescribed in Canada but carry significant risk of harm. There has been increasing clinical interest on the potential "sparing effects" of medical cannabis as one strategy to reduce benzodiazepine use. The objective of this study as to examine the association of medical cannabis authorization with benzodiazepine usage between 2013 and 2021 in Alberta, Canada.
public, environmental & occupational health
What problem does this paper attempt to address?